Godschalk M F, Chen J, Katz P G, Mulligan T
Division of Geriatrics, Medical College of Virginia, Richmond.
J Urol. 1994 Jun;151(6):1530-2. doi: 10.1016/s0022-5347(17)35293-x.
We report a double-blind, randomized, placebo-controlled, dose-response study of prostaglandin E1 as treatment for erectile failure. A total of 15 men 55.8 +/- 9.2 years old with a mean duration of erectile dysfunction of 7.6 years participated. During phase 1 (double-blind) subjects received injections of prostaglandin E1 twice weekly at doses of 0 micrograms. (placebo), 2.5 micrograms., 5.0 micrograms., 7.5 micrograms. and 10 micrograms. During phase 2 (nonblind) the dose was increased until a full erection or intolerance developed. Response was measured using a RigiScan monitor. During phase 3 the subjects injected prostaglandin E1 at home. Of the subjects 66% achieved an erection adequate for intercourse, with an average rigidity of 59%. The dose-response curve reached a plateau at 5 to 10 micrograms. Among those responding to prostaglandin E1 intercourse was rated satisfactory by 81% of the subjects and by 90% of the partners. There were no prolonged erections requiring reversal and pain was reported with only 10% of the injections. In summary, intracavernous prostaglandin E1 is an efficacious and effective treatment for erectile failure.
我们报告了一项关于前列腺素E1治疗勃起功能障碍的双盲、随机、安慰剂对照、剂量反应研究。共有15名年龄为55.8±9.2岁、平均勃起功能障碍持续时间为7.6年的男性参与。在第1阶段（双盲），受试者每周接受两次前列腺素E1注射，剂量分别为0微克（安慰剂）、2.5微克、5.0微克、7.5微克和10微克。在第2阶段（非盲），剂量增加直至出现完全勃起或不耐受。使用RigiScan监测仪测量反应。在第3阶段，受试者在家中自行注射前列腺素E1。66%的受试者实现了足以进行性交的勃起，平均硬度为59%。剂量反应曲线在5至10微克时达到平台期。在对前列腺素E1有反应的受试者中，81%的受试者和90%的伴侣认为性交令人满意。没有出现需要处理的持续性勃起，仅10%的注射报告有疼痛。总之，海绵体内注射前列腺素E1是治疗勃起功能障碍的一种有效疗法。
